Madison Avenue Partners, LP
13F filer · CIK 0001801265Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$2.32BU.S. long equity reported on 13F
Positions257 new · 9 closed
Net flow last quarter-$1.29BBuys minus sells
Top 10 positions weight77.1%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202625 positions | |||||
| $281M | 12.11% | Not reported | +0.2% | Q1 2020 | |
| $252M | 10.84% | 1.41% | New | Q2 2026 | |
| $219M | 9.44% | 0.90% | +27.8% | Q1 2025 | |
| $216M | 9.31% | Not reported | +33.0% | Q1 2026 | |
| $190M | 8.16% | 1.78% | -4.8% | Q4 2025 | |
| TBTBPHTheravance Biopharma, Inc. | $157M | 6.74% | 17.75% | -3.1% | Q3 2021 |
| $134M | 5.78% | 1.02% | -7.2% | Q2 2024 | |
| $120M | 5.16% | 8.39% | +71.0% | Q1 2026 | |
| $118M | 5.08% | 2.36% | -33.4% | Q2 2023 | |
| $103M | 4.45% | 5.23% | +39.9% | Q2 2025 | |
| $73.9M | 3.18% | 0.69% | +30.4% | Q1 2024 | |
| $68.8M | 2.96% | Not reported | New | Q2 2026 | |
| $64.4M | 2.77% | 0.05% | -7.2% | Q3 2025 | |
| $59.5M | 2.56% | 3.23% | Not reported | Q3 2021 | |
| $47.7M | 2.05% | 0.35% | New | Q2 2026 | |
| $45.8M | 1.97% | 0.86% | New | Q2 2026 | |
| ADADArray Digital Infrastructure, Inc. | $40.2M | 1.73% | 1.28% | New | Q2 2026 |
| $36.8M | 1.58% | 8.64% | Not reported | Q3 2022 | |
| $22.1M | 0.95% | 0.01% | -98.4% | Q2 2025 | |
| $21M | 0.90% | 1.28% | 0.0% | Q4 2025 | |
| $19.7M | 0.85% | Not reported | -6.1% | Q4 2025 | |
| $15.3M | 0.66% | 3.64% | -18.1% | Q4 2024 | |
| $8.97M | 0.39% | Not reported | Not reported | Q2 2025 | |
| $6.7M | 0.29% | 3.16% | Not reported | Q2 2025 | |
| $1.64M | 0.07% | 0.32% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202627 positions | |||||
| $393M | 17.10% | 0.42% | -56.8% | Q2 2025 | |
| $260M | 11.30% | Not reported | Not reported | Q1 2020 | |
| $177M | 7.69% | Not reported | New | Q1 2026 | |
| $171M | 7.44% | 1.87% | +78.0% | Q4 2025 | |
| $168M | 7.32% | 0.70% | Not reported | Q1 2025 | |
| TBTBPHTheravance Biopharma, Inc. | $154M | 6.71% | 18.46% | Not reported | Q3 2021 |
| $142M | 6.17% | 1.67% | New | Q1 2026 | |
| $132M | 5.72% | 3.45% | -31.3% | Q2 2023 | |
| $122M | 5.33% | 1.08% | -5.7% | Q2 2024 | |
| $84.5M | 3.67% | 1.22% | Not reported | Q4 2025 | |
| $74M | 3.22% | 3.74% | +11.4% | Q2 2025 | |
| $65.7M | 2.86% | 0.05% | -8.2% | Q3 2025 | |
| $61.8M | 2.69% | 0.53% | -72.7% | Q1 2024 | |
| $50.4M | 2.19% | 3.16% | Not reported | Q3 2021 | |
| $50.4M | 2.19% | 8.76% | Not reported | Q3 2022 | |
| $45.7M | 1.99% | 4.93% | New | Q1 2026 | |
| $25.8M | 1.12% | 1.11% | -40.9% | Q1 2024 | |
| $24.9M | 1.08% | 0.36% | New | Q1 2026 | |
| $21.5M | 0.93% | 1.29% | Not reported | Q4 2025 | |
| $19.1M | 0.83% | Not reported | +62.0% | Q4 2025 | |
| $16.3M | 0.71% | 0.75% | New | Q1 2026 | |
| $15.1M | 0.66% | 4.43% | -10.7% | Q4 2024 | |
| $10.7M | 0.46% | 0.19% | -55.2% | Q4 2025 | |
| $6.92M | 0.30% | 3.18% | -23.9% | Q2 2025 | |
| $5.97M | 0.26% | 1.09% | New | Q1 2026 | |
| $718K | 0.03% | 1.04% | -52.1% | Q3 2022 | |
| $651K | 0.03% | 0.00% | Not reported | Q3 2023 | |
| Q4 2025Reported Feb 17, 202623 positions | |||||
| $340M | 14.63% | 0.98% | -30.5% | Q2 2025 | |
| $270M | 11.60% | Not reported | Not reported | Q1 2020 | |
| $229M | 9.85% | 1.96% | +3.0% | Q1 2024 | |
| $225M | 9.68% | 5.03% | -2.8% | Q2 2023 | |
| $189M | 8.12% | 0.70% | +4.3% | Q1 2025 | |
| TBTBPHTheravance Biopharma, Inc. | $178M | 7.65% | 18.62% | Not reported | Q3 2021 |
| $158M | 6.77% | 1.15% | 0.0% | Q2 2024 | |
| $135M | 5.81% | 1.75% | New | Q4 2025 | |
| $110M | 4.73% | 1.24% | New | Q4 2025 | |
| $102M | 4.38% | 1.05% | New | Q4 2025 | |
| $72.4M | 3.11% | 3.36% | +0.8% | Q2 2025 | |
| $69.3M | 2.98% | 0.05% | Not reported | Q3 2025 | |
| $58.6M | 2.52% | 1.53% | New | Q4 2025 | |
| $39.2M | 1.68% | 3.18% | Not reported | Q3 2021 | |
| $35.1M | 1.51% | 1.88% | -2.0% | Q1 2024 | |
| $27M | 1.16% | 5.00% | -37.1% | Q4 2024 | |
| $26.9M | 1.15% | 1.30% | New | Q4 2025 | |
| $24M | 1.03% | Not reported | New | Q4 2025 | |
| $16.8M | 0.72% | 4.21% | -69.6% | Q2 2025 | |
| $13.9M | 0.60% | Not reported | New | Q4 2025 | |
| $5.17M | 0.22% | Not reported | New | Q4 2025 | |
| $2.13M | 0.09% | 2.17% | -12.7% | Q3 2022 | |
| $688K | 0.03% | 0.00% | Not reported | Q3 2023 | |
| Q3 2025Reported Nov 14, 202520 positions | |||||
| $289M | 17.27% | Not reported | +0.2% | Q1 2020 | |
| $231M | 13.81% | 1.41% | -42.2% | Q2 2025 | |
| $161M | 9.62% | 0.67% | Not reported | Q1 2025 | |
| $156M | 9.30% | 5.18% | -18.4% | Q2 2023 | |
| $146M | 8.71% | 1.89% | +48.8% | Q1 2024 | |
| $145M | 8.66% | 1.15% | -11.4% | Q2 2024 | |
| TBTBPHTheravance Biopharma, Inc. | $139M | 8.29% | 18.77% | Not reported | Q3 2021 |
| $76.1M | 4.54% | 3.33% | +17.0% | Q2 2025 | |
| $65M | 3.88% | 0.05% | New | Q3 2025 | |
| $47.4M | 2.83% | 1.92% | -43.0% | Q1 2024 | |
| $45.1M | 2.69% | 3.10% | Not reported | Q3 2021 | |
| $44.6M | 2.66% | 0.25% | Not reported | Q2 2024 | |
| $42.8M | 2.56% | 6.67% | +0.6% | Q2 2025 | |
| $33.2M | 1.98% | 7.96% | -15.3% | Q4 2024 | |
| $28.7M | 1.71% | 2.58% | +145.4% | Q3 2022 | |
| $14.7M | 0.88% | 0.78% | New | Q3 2025 | |
| $4.13M | 0.25% | 2.49% | Not reported | Q3 2022 | |
| $3.95M | 0.24% | Not reported | -78.1% | Q1 2024 | |
| $1.67M | 0.10% | Not reported | -77.3% | Q2 2025 | |
| $635K | 0.04% | 0.00% | Not reported | Q3 2023 | |
Premium opens every quarter this fund has filed